-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Coronavirus disease 19 (COVID-19) causes a broad spectrum of clinical illness ranging from upper respiratory symptoms to severe respiratory failure and death
Background: Coronavirus disease 19 (COVID-19) causes a broad spectrum of clinical illness ranging from upper respiratory symptoms to severe respiratory failure and death
Receptor for advanced glycation end products (RAGE) and its soluble form, sRAGE, are predominantly expressed by type I alveolar cells and have been well characterized as a marker of lung type I alveolar epithelial cell damage and a diagnostic and prognostic biomarker for ARDS
The overall objective of this study was to measure plasma sRAGE in a well-characterized cohort of subjects in a multicenter, prospective, randomized, controlled trial of the neutralizing monoclonal antibody bamlanivimab in hospitalized patients
Methods: Baseline levels were measured in participants in the bamlanivimab ACTIV-3/TICO trial for hospitalized patients with COVID-19
RESULTS: In 277 participants, baseline sRAGE was strongly associated with viral plasma antigen concentrations (r = 0.
Figure 1 log 2 - Converted plasma sRAGE concentrations (pg/mL), across baseline oxygen demand levels
Figure 1 log 2 - Converted plasma sRAGE concentrations (pg/mL), across baseline oxygen demand levels
Figure 2 Cumulative incidence of sustained recovery (dashed line) and death (solid line), stratified by sRAGE ≥ 6800 pg/mL versus < 6800 pg/mL
Figure 2 Cumulative incidence of sustained recovery (dashed line) and death (solid line), stratified by sRAGE ≥ 6800 pg/mL versus < 6800 pg/mL
Conclusion: Elevated plasma sRAGE in hospitalized non-ventilated patients with COVID-19 is an indicator of clinical disease severity and plasma viral load
Source: Wick KD, Siegel L, Neaton JD, et al.
RAGE has potential pathogenetic and prognostic value in non-intubated hospitalized patients with COVID-19 .
JCI Insight 2022 Mar 17 RAGE has potential pathogenetic and prognostic value in non-intubated hospitalized patients with .
Leave a
message here
